What is Cymbalta®?

We are no longer accepting new Cymbalta withdrawal cases.

​Duloxetine hydrochloride, marketed as Cymbalta®, is a selective serotonin norepinephrine reuptake inhibitor (SSNRI but more commonly known as an SNRI) prescription antidepressant drug used to treat major depression. It is also used to treat anxiety, pain associated with diabetes, for the management of fibromyalgia, and for chronic muscle or bone pain.

Eli Lilly and Company, a major pharmaceutical and antidepressant drug manufacturer, manufacturers and markets Cymbalta. The U.S. Food and Drug Administration (FDA) first approved Cymbalta on August 3, 2004.

The FDA placed Cymbalta as a pregnancy “category C” drug. The FDA uses the category system to determine possible risks to a fetus when medicines are taken during pregnancy. When a drug is placed in category C, it means that the drug has not been studied in pregnant women, but has shown harmful side effects on fetuses in animal testing.

The first generic versions of Cymbalta (duloxetine delayed-release capsules), were approved by the FDA in December of 2013.

What is Cymbalta Used For?

Cymbalta Details:

Pharmaceutical: Cymbalta
Manufacturer: Eli Lilly and Company
Generic name: Duloxetine (or duloxetine hydrochloride)
Drug Class: Selective norepinephrine reuptake inhibitor (SNRI) antidepressant
CAS Number: 59729-33-8

Guidelines:

Cymbalta, known generically as duloxetine, is in the class of antidepressant drugs known as serotonin and norepinephrine reuptake inhibitors (SNRIs). SNRI antidepressants are believed to function by increasing levels of the neurotransmitters serotonin and norepinephrine in the synaptic cleft. Cymbalta is used to treat
major depressive disorder (MDD) general anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia (FM), osteoarthritis, and chronic musculoskeletal pain. It is available in 20 mg., 30 mg., and 60 mg. tablets.

Contraindications:

The use of Cymbalta with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serious drug interactions that can be fatal (see section on Serious Adverse Outcomes below). Cymbalta is also contraindicated for patients with narrow-angle glaucoma.

Common Adverse Outcomes: [ From Physician’s Desk Reference 2013 ]

  • Nausea
  • Headache
  • Dry mouth
  • Fatigue, weakness
  • Sleepiness
  • Insomnia
  • Constipation
  • Dizziness
  • Diarrhea
  • Decreased appetite, anorexia
  • Excessive sweating
  • Abdominal pain
  • Sexual dysfunction

Serious Adverse Outcome:

The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs (including Cymbalta) and SSRIs alone, and when these drugs are used with medications that impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include:

  • Mental status changes
    • agitation
    • hallucinations
    • coma
  • Autonomic instability status changes
    • tachycardia (fast heart rate)
    • blood pressure changes
    • hyperthermia (high temperature)
  • Neuromuscular aberrations
    • hyperreflexia (overactive bodily reflexes)
    • incoordination
  • Gastrointestinal symptoms
    • nausea
    • vomiting
    • diarrhea

Serotonin syndrome, in its most severe form, can resemble neuroleptic malignant syndrome, which includes high temperature, muscle rigidity, and autonomic instability (refers to the autonomic nervous system, which controls heart rate, breathing rate, body temperature, digestion, etc.), with possible rapid fluctuation of vital signs and mental status changes.

Warnings:

  • Suicide Risk: Cymbalta carries the following black box warning on its label: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.
  • Liver Failure: There have been reports of hepatic failure, sometimes fatal, in patients treated with Cymbalta
  • Abnormal Bleeding: SSRIs and SNRIs, including Cymbalta, increase the risk of bleeding events.

What is Cymbalta Withdrawal?

Discontinuing Cymbalta:

The Cymbalta label states: “Discontinuation symptoms have been systematically evaluated in patients taking duloxetine. Following abrupt or tapered discontinuation in placebo-controlled clinical trials, the following symptoms occurred at a rate greater than or equal to 1% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia [brain zaps], irritability, vomiting, insomnia, anxiety, hyperhidrosis [excessive sweating], and fatigue.”

The label also states: “Symptoms associated with discontinuation of Cymbalta and other SSRIs and SNRIs have been reported. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible [see Warnings and Precautions].” The Warnings and Precautions section states, “All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.”

Medical Studies:

  • “Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder,” Journal of Affective Disorders (89) 2005.
  • “Duloxetine in the Treatment of Depression. A Double-Blind Placebo-Controlled Comparison with Paroxetine,” Journal of Clinical Psychopharmacology 24 (4), August 2004.

Pregnancy Category:

The FDA classifies Cymbalta as a Pregnancy Category C, which means there is no controlled data in human pregnancy studies but animal studies have shown an adverse effect on the fetus.

Get Started
Call (310) 207-3233 or fill out the form below and request a free consultation.
20,000+ Families Represented

"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"

Mary Flores
Reviewed
on Google
Read More Reviews
Case Results
We Demand Accountability.
More Successful Results
$2.0 Billion Verdict
Personal Injury
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case. The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case. The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
Continue Reading
$2.0 Billion Verdict
Personal Injury

In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.

The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.

$289.2 Million Verdict
Personal Injury
$289.2 million jury verdict in Monsanto Roundup trial Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma. Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million. Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
$289.2 million jury verdict in Monsanto Roundup trial Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma. Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million. Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
Continue Reading
$289.2 Million Verdict
Personal Injury

$289.2 million jury verdict in Monsanto Roundup trial

Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.

Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.

Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.

$265 Million Settlement
Fatal Train Crash
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
Continue Reading
$265 Million Settlement
Fatal Train Crash

In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.

When powerful systems fail, we step in. Wisner Baum exposes injustice, demands accountability, and delivers real results for those who’ve been harmed. Justice Starts Here.
Los Angeles
11111 Santa Monica
Blvd Suite 1750
Los Angeles, CA 90025
Get Directions
Bay Area
100 Drakes Landing Road
Suite 160
Greenbrae, CA 9490412
Get Directions
Washington, D.C.
2101 L St NW 

Suite 800
Washington, DC 20037
Get Directions
The information on this website is for general information purposes only. Nothing on this site should be taken as advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute a client relationship.
Send Us Your Case Details
We’ll respond and let you know the best way to proceed with your case.
crossarrow-up linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram